Skip to main content
Top
Published in: Cancer Imaging 1/2024

Open Access 01-12-2024 | Pulmonary Nodule | Research article

Comparison of different classification systems for pulmonary nodules: a multicenter retrospective study in China

Authors: Feipeng Song, Qian Yang, Tong Gong, Kai Sun, Wenjia Zhang, Mengxi Liu, Fajin Lv

Published in: Cancer Imaging | Issue 1/2024

Login to get access

Abstract

Background

To compare the diagnostic performance of Lung-RADS (lung imaging-reporting and data system) 2022 and PNI-GARS (pulmonary node imaging-grading and reporting system).

Methods

Pulmonary nodules (PNs) were selected at four centers, namely, CQ Center (January 1, 2018-December 31, 2021), HB Center (January 1, 2021–June 30, 2022), SC Center (September 1, 2021–December 31, 2021), and SX Center (January 1, 2021–December 31, 2021). PNs were divided into solid nodules (SNs), partial solid nodules (PSNs) and ground-glass nodules (GGNs), and they were then classified by the Lung-RADS and PNI-GARS. The sensitivity, specificity and agreement rate were compared between the two systems by the χ2 test.

Results

For SN and PSN, the sensitivity of PNI-GARS and Lung-RADS was close (SN 99.8% vs. 99.4%, P < 0.001; PSN 99.9% vs. 98.4%, P = 0.015), but the specificity (SN 51.2% > 35.1%, PSN 13.3% > 5.7%, all P < 0.001) and agreement rate (SN 81.1% > 74.5%, P < 0.001, PSN 94.6% > 92.7%, all P < 0.05) of PNI-GARS were superior to those of Lung-RADS. For GGN, the sensitivity (96.5%) and agreement rate (88.6%) of PNI-GARS were better than those of Lung-RADS (0, 18.5%, P < 0.001). For the whole sample, the sensitivity (98.5%) and agreement rate (87.0%) of PNI-GARS were better than Lung-RADS (57.5%, 56.5%, all P < 0.001), whereas the specificity was slightly lower (49.8% < 53.4%, P = 0.003).

Conclusion

PNI-GARS was superior to Lung-RADS in diagnostic performance, especially for GGN.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bray F, Laversanne M, Weiderpass E, et al. The ever-increasing importance of cancer as a leading cause of premature death worldwide[J]. Cancer. 2021;127(16):3029–30. 10.1002/ cncr.33587.CrossRefPubMed Bray F, Laversanne M, Weiderpass E, et al. The ever-increasing importance of cancer as a leading cause of premature death worldwide[J]. Cancer. 2021;127(16):3029–30. 10.1002/ cncr.33587.CrossRefPubMed
10.
go back to reference Bhandari S, Tripathi P, Pham D, et al. Performance of community-based Lung cancer screening program in a Histoplasma endemic region[J]. Lung Cancer. 2019;136:102–4. 10.1016/j. lungcan.2019.08.026.CrossRefPubMed Bhandari S, Tripathi P, Pham D, et al. Performance of community-based Lung cancer screening program in a Histoplasma endemic region[J]. Lung Cancer. 2019;136:102–4. 10.1016/j. lungcan.2019.08.026.CrossRefPubMed
12.
go back to reference Pinsky PF, Gierada DS, Black W et al. Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment[J]. Ann Intern Med 2015,162(7):485–91. 10.7326/ M14-2086. Pinsky PF, Gierada DS, Black W et al. Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment[J]. Ann Intern Med 2015,162(7):485–91. 10.7326/ M14-2086.
13.
go back to reference Kim H, Goo JM, Kim TJ, et al. Effectiveness of radiologist training in improving reader agreement for Lung-RADS 4X categorization[J]. Eur Radiol. 2021;31(11):8147–59. 10.1007 /s00330-021-07990-y.CrossRefPubMed Kim H, Goo JM, Kim TJ, et al. Effectiveness of radiologist training in improving reader agreement for Lung-RADS 4X categorization[J]. Eur Radiol. 2021;31(11):8147–59. 10.1007 /s00330-021-07990-y.CrossRefPubMed
15.
go back to reference Kim YK, Lee SH, Seo JH et al. A comprehensive model of factors affecting adoption of clinical practice guidelines in Korea[J]. J Korean Med Sci 2010,25(11):1568–73. 10.3346/ jkms.2010.25.11.1568. Kim YK, Lee SH, Seo JH et al. A comprehensive model of factors affecting adoption of clinical practice guidelines in Korea[J]. J Korean Med Sci 2010,25(11):1568–73. 10.3346/ jkms.2010.25.11.1568.
17.
go back to reference Zhang Y, Fajin L, Zhigang C, et al. Evaluation of Benign and Malignant Pulmonary nodules based on thin-layer CT imaging Features[J]. Chin J Med Imaging. 2019;27(3):182–7. Zhang Y, Fajin L, Zhigang C, et al. Evaluation of Benign and Malignant Pulmonary nodules based on thin-layer CT imaging Features[J]. Chin J Med Imaging. 2019;27(3):182–7.
18.
go back to reference Zhang Y. A study on differentiation of benign and malignant pulmonary nodules based on imaging features [D]. Chongqing: Chongqing Medical University; 2019. Zhang Y. A study on differentiation of benign and malignant pulmonary nodules based on imaging features [D]. Chongqing: Chongqing Medical University; 2019.
19.
go back to reference Bankier AA, MacMahon H, Goo JM et al. Recommendations for Measuring Pulmonary Nodules at CT: A Statement from the Fleischner Society[J]. Radiology,2017,285(2):584–600. 10.1148/ radiol. 2017162894. Bankier AA, MacMahon H, Goo JM et al. Recommendations for Measuring Pulmonary Nodules at CT: A Statement from the Fleischner Society[J]. Radiology,2017,285(2):584–600. 10.1148/ radiol. 2017162894.
21.
go back to reference Yu JY, Lee B, Ju S et al. Proportion and characteristics of transient nodules in a retrospective analysis of pulmonary nodules[J]. Thorac Cancer,2012,3(3):224–228. 10.1111/ j.1759–7714. 2011.00101.x. PMID: 28920303. Yu JY, Lee B, Ju S et al. Proportion and characteristics of transient nodules in a retrospective analysis of pulmonary nodules[J]. Thorac Cancer,2012,3(3):224–228. 10.1111/ j.1759–7714. 2011.00101.x. PMID: 28920303.
Metadata
Title
Comparison of different classification systems for pulmonary nodules: a multicenter retrospective study in China
Authors
Feipeng Song
Qian Yang
Tong Gong
Kai Sun
Wenjia Zhang
Mengxi Liu
Fajin Lv
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cancer Imaging / Issue 1/2024
Electronic ISSN: 1470-7330
DOI
https://doi.org/10.1186/s40644-023-00634-y

Other articles of this Issue 1/2024

Cancer Imaging 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine